All articles tagged with #health and medicine
A Finnish study finds that a 30-minute sauna session, including a brief cold shower, causes a temporary surge in white blood cells, potentially enhancing immune surveillance.
Researchers at the Norwegian University of Science and Technology (NTNU) have discovered that Janus kinase (JAK) inhibitors, a class of anti-inflammatory drugs widely prescribed for conditions like rheumatoid arthritis, may inadvertently facilitate the spread of dangerous viruses. The study, published in NAR Molecular Medicine, indicates that these medications suppress specific immune signaling pathways and gene activities that normally protect cells from viral infection. This suppression can leave patients more vulnerable to pathogens such as influenza, SARS-CoV-2, adenovirus, and Rift Valley fever virus. While the drugs are effective for managing inflammation, the findings suggest a significant trade-off: they may compromise innate antiviral defenses, potentially allowing viruses to establish infections and propagate more easily within the body. The researchers recommend caution when prescribing these medications during periods of high viral transmission or for patients with active or latent infections.
Researchers at NYU Langone Health have mapped how pancreatic cancer cells genetically reorganize to resist treatment and evade the immune system. By analyzing nearly 450,000 individual cells, they found that blocking the MYC gene can reverse aggressive tumor states, potentially improving immunotherapy outcomes.
A new clinical trial suggests that stimulating nerves in the ear via a small handheld device may help lower blood pressure in patients with severe hypertension, though it did not show significant benefits for the general group. The study, conducted by Queen Mary University of London, found the treatment safe and easy to use at home. While overall results were not statistically significant compared to a placebo, a specific subgroup with uncontrolled high blood pressure showed promising reductions. Researchers emphasize that larger studies are needed to confirm these findings and determine which patients benefit most. This approach offers a potential non-invasive alternative to current medications for those struggling to manage their condition.
A phase 2 clinical trial published in CANCER indicates that daily oral vitamin C supplementation may improve survival rates for patients with precancerous blood disorders. The study found that while the supplement did not slow the growth of abnormal cells, it reduced adverse events and was associated with better long-term survival outcomes.
A new study in Nature suggests that losartan, a common blood pressure medication, can stimulate brown fat activity, potentially boosting metabolism and reducing risks for heart disease and depression. Researchers analyzed over 100,000 patient scans and confirmed in mice that the drug activates brown fat through mechanisms distinct from its blood pressure effects.
Researchers at the University of British Columbia have identified the molecular mechanism behind statin-induced muscle pain. Using cryo-electron microscopy, they found that three statin molecules bind to the ryanodine receptor (RyR1) in muscle cells, forcing it open and causing a continuous leak of calcium. This unregulated calcium flow damages muscle tissue, explaining side effects ranging from mild soreness to severe breakdown. The findings, published in Nature Communications, provide a structural roadmap for designing next-generation statins that lower cholesterol without triggering this harmful interaction, potentially improving tolerance for the 200 million people worldwide who rely on these drugs.
A new study identifies Miro1, a mitochondrial membrane protein, as a central regulator of insulin resistance in type 2 diabetes. Researchers found that Miro1 accumulates in the skeletal muscle of diabetic patients and mice, impairing glucose uptake and oxidative capacity. This buildup results from defective insulin signaling at the mitochondrial level, specifically a failure of AKT to interact with Miro1. Crucially, a randomized controlled trial demonstrated that 12 weeks of exercise training reduces Miro1 accumulation, improves mitochondrial structure, and restores insulin sensitivity. Genetic deletion of Miro1 in mice confirmed that its removal enhances glucose disposal and mitochondrial function, suggesting it as a potential therapeutic target.
Researchers at Mount Sinai have identified three specific white matter pathways that are essential for long-term relief in patients with severe depression treated via deep brain stimulation (DBS). Published in the American Journal of Psychiatry, the study analyzed the largest multicohort group to date, including data from the BROADEN trial and the University of Toronto. The findings indicate that successful outcomes depend on stimulating the cingulum bundle, forceps minor, and medial uncinate fasciculus/ventral amygdalofugal pathway. Patients who failed to improve after two years consistently showed insufficient engagement of the left cingulum bundle. This suggests that precise, connectivity-based electrode placement is more critical than general anatomical positioning. The results support the use of individualized brain maps to guide surgical targeting, potentially improving the efficacy of this experimental therapy for those who do not respond to conventional treatments.
A large-scale study published in Nature reveals that the common blood pressure medication losartan can activate brown adipose tissue (BAT), potentially boosting metabolism. By analyzing over 100,000 patient records, researchers found that individuals with active BAT have significantly lower risks of cardiovascular and psychiatric conditions. This suggests losartan could be repurposed to treat metabolic disorders, independent of its blood pressure effects.
A new study from Rutgers University links popular GLP-1 medications, including Ozempic and Wegovy, to a slightly elevated risk of ischemic optic neuropathy, a rare condition causing sudden and potentially permanent vision loss. While the absolute risk is low, estimated at three to four additional cases per 10,000 patients over 18 months, the findings highlight the need for vigilance among millions of users. This scientific data emerges as hundreds of lawsuits allege that manufacturers failed to warn patients about this specific side effect.
A recent 84-day clinical trial in China found that a standardized high-fiber diet produced better improvements in blood sugar control and body weight than metformin monotherapy in adults with newly diagnosed type 2 diabetes and obesity. The study, published in Frontiers in Microbiology, highlights the potential of dietary interventions to reshape the gut microbiome and enhance metabolic health, though researchers caution that larger trials are needed before changing clinical guidelines.
Dr. Melissa Walton-Shirley, a retired cardiologist, details her personal experience using beetroot supplements to manage resistant hypertension. While initial studies suggest beetroot can lower blood pressure by boosting nitric oxide, her case highlights potential risks. She developed severe neurologic symptoms, including ataxia and visual disturbances, which resolved after stopping the supplements. She attributes this to the trigeminovascular cascade triggered by increased cyclic guanosine monophosphate (cGMP). The article serves as a cautionary tale for patients and clinicians regarding over-the-counter nitrate sources.
Researchers led by Lige Leng at Xiamen University found that declining levels of the protein Menin in the hypothalamus drive systemic aging and cognitive loss in mice. Restoring Menin reversed age-related physical and mental decline within 30 days. Additionally, supplementing with the amino acid D-serine improved memory in three weeks, though it did not restore bone or skin health. While promising, human trials remain limited and D-serine effects vary by biological context.
The disappointing results of the Lp(a)HORIZON trial, which showed that the drug pelacarsen did not reduce major cardiovascular events despite lowering lipoprotein(a) levels, have not ended the search for Lp(a)-targeted therapies. Experts argue that differences in drug potency and trial design mean that other phase 3 trials, such as Amgen’s OCEAN(a) and Eli Lilly’s ACCLAIM-Lp(a), may still succeed. While pelacarsen reduced Lp(a) by 80%, newer small interfering RNA therapies achieve reductions exceeding 90%. Although the HORIZON failure raises questions about whether Lp(a) is a viable treatment target or merely a risk marker, clinicians emphasize that Lp(a) remains a crucial diagnostic tool for assessing cardiovascular risk.